Literature DB >> 3262701

Effect of ketorolac on Pseudomonas aeruginosa ocular infection in rabbits.

E B Fraser-Smith1, T R Matthews.   

Abstract

Corticosteroids can exacerbate bacterial ocular infections, even in the presence of antibiotics. Ketorolac tromethamine is a new non-steroidal compound being considered as an anti-inflammatory ophthalmic drug. In this study, rabbits ocularly infected with Pseudomonas aeruginosa were treated topically with 0.4 percent tobramycin sulfate 4 times daily for 7 days to control infection. At the same times, either 0.5 percent ketorolac, 0.1 percent dexamethasone or vehicle was also given topically. Animals were scored for severity of both conjunctivitis (maximum severity rates score of 10) and corneal opacity (maximum of 4) using the Draize scale. Severity of the infection was determined by counting the number of punctate lesions which developed on the cornea. Nine days after treatment ended, the number of these lesions was the same for ketorolac as for the vehicle (respectively, 16.7 +/- 3 and 13.8 +/- 3, mean +/- SE, n = 24), indicating no exacerbation of the infection, whereas with dexamethasone these parameters increased (30.2 +/- 4, n = 24). During treatment, ketorolac reduced conjunctivitis (1.8 +/- 0.2, n = 120) when compared with the vehicle (2.9 +/- 0.2, n = 120), whereas dexamethasone did not (3.8 +/- 0.2, n V 120); neither ketorolac nor dexamethasone reduced corneal opacity (respectively, 2.3 +/- 0.05 and 2.6 +/- 0.1, n = 24) compared with vehicle (2.2 +/- 0.05, n = 24). After treatment, both conjunctivitis and corneal opacity became more severe only in dexamethasone treated eyes (respectively, 4.4 +/- 0.2, n = 120 and 3.0 +/- 0.02, n = 24). Thus, ketorolac appears to be an anti-inflammatory agent that does not worsen bacterial ocular infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262701     DOI: 10.1089/jop.1988.4.101

Source DB:  PubMed          Journal:  J Ocul Pharmacol        ISSN: 8756-3320


  5 in total

1.  In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: a technical note.

Authors:  Manjusha Malhotra; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2005-10-24       Impact factor: 3.246

2.  Aqueous, oil, and ointment formulations of ketorolac: efficacy against prostaglandin E2-induced ocular inflammation and safety: a technical note.

Authors:  Manjusha Malhotra; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2006       Impact factor: 3.246

Review 3.  The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology.

Authors:  P Koay
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

Review 4.  Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  M M Buckley; R N Brogden
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

5.  Changing trends in the clinical course and outcome of bacterial keratitis at King Khaled Eye Specialist Hospital.

Authors:  Ali Al-Shehri; Sabah Jastaneiah; Michael D Wagoner
Journal:  Int Ophthalmol       Date:  2008-04-03       Impact factor: 2.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.